

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 31/77</b>		<b>A2</b>	(11) International Publication Number: <b>WO 96/30028</b>
			(43) International Publication Date: 3 October 1996 (03.10.96)
(21) International Application Number: PCT/US96/04309			<b>(81) Designated States:</b> AL, AM, AT, AT (Utility model), AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), EE, EE (Utility model), ES, FI, FI (Utility model), GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 29 March 1996 (29.03.96)			
(30) Priority Data: 413,699 30 March 1995 (30.03.95) US			
(60) Parent Application or Grant (63) Related by Continuation US 08/413,699 (CIP) Filed on 30 March 1995 (30.03.95)			
(71) Applicant (for all designated States except US): DUKE UNIVERSITY [US/US]; 230 North Building, Research Drive, Durham, NC 27708-0083 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): GHIO, Andrew, J. [US/US]; 211 Brandemill Drive, Durham, NC 27713 (US). PIANTADOSI, Claude, A. [US/US]; 3808 Kildrummy Drive, Durham, NC 27705 (US). KENNEDY, Thomas, P. [US/US]; 213 Grande Drive, Richmond, VA 23229 (US).			
(74) Agents: McCOY, Michael, D. et al.; Bell, Seltzer, Park & Gibson, P.O. Drawer 34009, Charlotte, NC 28234 (US).			
<b>(54) Title:</b> METHOD OF MUCOCILIARY CLEARANCE IN CYSTIC FIBROSIS PATIENTS USING ALKYLARYL POLYETHER ALCOHOL POLYMERS			
<b>(57) Abstract</b>  A method and medicament for the inhibition of oxidants comprising administering a treatment effective amount of alkylaryl polyether alcohol polymers to a chemical or biologic system in need thereof. Also, a method and medicament for mucociliary clearance, inhibition of cytokine production, and inhibition of interleukin-8 production in cystic fibrosis patients. The method involves administering a treatment effective amount of alkylaryl polyether alcohol polymers to a chemical or biologic system in need thereof. The medicament is preferably administered by aerosolization into the mammalian respiratory system. The medicament may also be applied to the mammalian skin. Preferably, the medicament includes a physiologically acceptable carrier which may be selected from the group consisting of physiologically buffered saline, isotonic saline, normal saline, petrolatum based ointments and U.S.P. cold cream.			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

-1-

METHOD OF MUCOCILIARY CLEARANCE IN  
CYSTIC FIBROSIS PATIENTS USING  
ALKYLARYL POLYETHER ALCOHOL POLYMERS

BACKGROUND OF THE INVENTION

Field Of The Invention



The present invention relates to the use of alkylaryl polyether alcohol polymers in treatment of chronic pulmonary inflammation. More particularly, the present invention relates to use of alkylaryl polyether alcohol polymers to reduce the activation of nuclear fact-Kappa Beta and inhibit the secretion of pro-inflammatory cytokines TNF- $\alpha$ , interleukin-1 $\beta$ , interleukin-6, interleukin-8, and the growth factor GN-CSF.

The Prior Art

Discussion of oxidant-mediated injury.

Oxygen is life-giving to aerobic plants and animals who depend on it for energy metabolism. It can also be lethal to those same organisms when it is altered from its stable dioxygen ( $O_2$ ) state to any one of three partially reduced species: a) the one electron reduced form superoxide anion ( $O_2^{\cdot -}$ ); b) the two electron reduced form hydrogen peroxide ( $H_2O_2$ ); or the deadly three electron reduced form the hydroxyl radical ( $\cdot OH$ ). In biologic systems  $O_2^{\cdot -}$  and  $H_2O_2$  are metabolic byproducts of a host of enzymes (oxygenases) that use oxygen as a cofactor.  $H_2O_2$  is also produced from  $O_2^{\cdot -}$  by the enzymatic action of superoxide dismutases. However,  $\cdot OH$  is generally produced only when  $O_2^{\cdot -}$  and  $H_2O_2$  interact with transitional ions of metals such as iron and copper in dangerous cyclical redox reactions:

-2-



The above reactions are termed the superoxide-driven Fenton reaction common in biological systems. The Fenton reaction can also be initiated by other reducing substances such as ascorbate in the presence of ferric iron and  $\text{H}_2\text{O}_2$ .

While  $\cdot\text{O}_2^-$  and  $\text{H}_2\text{O}_2$  are each toxic for biological systems,  $\cdot\text{OH}$  (and its alternate hypothesized form the ferryl intermediate  $\text{FeO}^{2+}$ ) is a highly reactive species that can oxidize unsaturated membrane lipids, damage cellular proteins and cause mutagenic strand breaks in DNA. To prevent injury from partially reduced  $\text{O}_2$  species under normal conditions, cells have evolved an elaborate system of antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase) and antioxidant molecules (glutathione, alpha-tocopherol, beta carotene). However, when production of partially reduced  $\text{O}_2$  species exceeds the capacity of cellular antioxidant defenses to contain them, oxidant injury occurs.

A growing number of mammalian disease entities are now thought to be related to overproduction of partially reduced  $\text{O}_2$  species, including the reperfusion injury syndromes myocardial infarction and stroke, adult respiratory distress syndrome, oxygen toxicity of the lung, lung injury from asbestos, Parkinson's disease, thermal and solar burns of the skin, and injury to the gastrointestinal tract from nonsteroidal anti-inflammatory agents (see Table IV, page 60, Halliwell B and Gutteridge JMC. Methods in Enzymology (1990) 186:1-85). Treatment of these conditions is increasingly directed either toward

-3-

strategies that prevent enzymatic production of partially reduced O<sub>2</sub> species and to the introduction of exogenous antioxidant compounds that restore oxidant-antioxidant balance in biologic and chemical systems.

Discussion of cystic fibrosis.

The hallmark of cystic fibrosis is abundant production in a cystic fibrosis patient of thick, tenacious, purulent airway secretions that are difficult to clear, even with physiotherapy. These secretions obstruct airways and contribute greatly to the progression of obstructive lung disease by stagnating the inflammatory process within airways.

Cystic fibrosis is the most common lethal recessive genetic disease in the United States. (See, Di Sant' Agnese and Davis, "Cystic Fibrosis in Adults: 75 Cases and a Review of 232 Cases in the Literature," Am. J. Med. (1979) 66:121-132.) It is a disease primarily affecting those of northern European ancestry, and occurs once in every 1500 to 2000 Caucasian live births and once in every 17,000 Afro-American live births in the United States. (See, Steinbert and Brown, "On the Incidence of Cystic Fibrosis on the Pancreas," Am. J. Human Genet. (1969) 12:416-424; Kramm, Crane, Sinkin, and Brown, "A Cystic Fibrosis Pilot Survey in Three New England States," Am. J. Public Health (1962) 52:2041-2051; Merritt, Hanna, Todd, and Myers, "The Incidence and Mode of Inheritance of Cystic Fibrosis," J. Lab. Clin. Med. (1962) 60:990-999; and Shultz, Schlisinger, and Moser, "The Erie County Survey of Long Term Childhood Disease," Am. J. Public Health (1966) 56:1461-1469. About 5% of the population of the United States are carriers for the cystic fibrosis recessive gene. (See, Kramm et al., supra.) Of patients with cystic fibrosis, about 50% die before reaching the age of 21 years. (See, Di Sant'

-4-

Agrese and Davis, "Research in Cystic Fibrosis," New England J. Med. (1976) 295:481-488.) Accordingly, any intervention that improves the prognosis in this disease would have a major impact on childhood and adolescent mortality and morbidity from cystic fibrosis in the United States.

The major cause of mortality and morbidity in patients with cystic fibrosis is progressive pulmonary disease. (See, Stern, Boat, Doershuk, Tucker, Psimiano, and Matthews, "Course of Cystic Fibrosis in 95 Patients," J. Pediatrics (1976) 89:406-411.) Lung disease is not present at birth, but develops later, during childhood or adolescence. (See, Sturgess and Imrie, "Quantitative Evaluation of the Development of Tracheal Submucosal Glands in Infants with Cystic Fibrosis and Control Infants," Am. J. Pathol. (1992); 106:303-311; Davis, "Pathophysiology of Pulmonary Disease in Cystic Fibrosis," Seminars Respir. Med. (1985) 6:261-270; and Wood, Boat, and Doershuk, "Cystic Fibrosis," Am. Rev. Respir. Dis. (1969) 113:833-878.)

While the earliest events in the pathogenesis of cystic fibrosis lung disease are uncertain, inflammation of small airways is an early lesion. (See, Davis, supra.) The inflammation may be caused by early infection since patients with cystic fibrosis have distinctive respiratory flora. (See, Mearns, Hunt, Rushworth, "Bacterial Flora of the Respiratory Tract in Patients with Cystic Fibrosis, 1950-1971," Arch. Dis. Child (1972) 47:902-907; and May, Herrick, and Thompson, "Bacterial Infections in Cystic Fibrosis," Arch. Dis. Child (1972) 47:908-913.)

Staphylococcus aureus is generally the dominant organism early in the course of cystic fibrosis disease, and is supplanted later by Pseudomonas aeruginosa, especially mucoid strains. (See, Tococca, Sibringo, and Barbeso, "Respiratory Tract Bacteriology in Cystic Fibrosis," Am. J. Dis.

-5-

Child (1963) 106:315-325; and Doggett, Harrison, Stillwell, and Wallis, "An Atypical Pseudomonas aeruginosa Associated with Cystic Fibrosis of the Pancreas," J. Pediat. (1966) 68:215-221.)

- 5           As infections and inflammation become established in airways of the cystic fibrosis patient, hypertrophy and hyperplasia of the mucous-secreting apparatus develops, ciliated cells are replaced by goblet cells, and squamous metaplasia becomes
- 10 pronounced. Beneath impacted mucous, denudation and ulceration of the mucosa may occur. Gradually, this destruction progresses up the respiratory tree to involve the larger airways. Structural damage to the bronchial wall occurs, and bronchiectasis develops.
- 15 Bronchiectasis and mucopurulent plugging are present in most cystic fibrosis patients who come to necropsy after the age of two years. (See Bedrossian, Greenberg, and Gisner, "The Lung in Cystic Fibrosis," Human Pathol. (1976) 7:195-204.)
- 20           Several factors contribute to the progression of lung disease in cystic fibrosis patients, but important among them is the thick, viscous nature of airway mucous. Not only do thick secretions obstruct airways and contribute to reduced lung volumes and
- 25 expiratory flows, but they also cause the inflammatory process to stand within the airways, thereby exposing the airway mucosa to a more abundant protease and oxidant rich environment than if the purulent respiratory secretions were easily expectorated. The
- 30 enhanced viscoelastic properties of purulent secretions is due in part to the presence of highly polymerized, polyanionic deoxyribonucleic acid (DNA) from the nuclei of degenerating polymorphonuclear neutrophils (PMNs). (For a discussion of the characteristics of the mucous
- 35 or sputum from cystic fibrosis patients, see, for instance, Lethem et al. "The Role of Mucous Glycoproteins in the Rheologic Properties of Cystic



-6-

Fibrosis Sputus, "Am. Rev. Respir. Dis. (1990) 142:1053-1058.)

Also, contributing to sputum tenacity is the presence of abundant cross-linked actin filaments from the cytosol of PMNs. Strategies to reduce the viscoelasticity of cystic fibrosis sputum and render it more easily expectorated include aerosol administration of recombinant human DNase I (rhDNase), which is a naturally occurring extracellular enzyme, to lyse DNA, or aerosol administration of gelsolin, which is a normal intracellular-severing protein, to depolymerize actin. (For a discussion of treatment of cystic fibrosis, see, for instance, Cantin et al. "Protection by Antibiotics Against Myeloperoxidase-Dependent Cytotoxicity to Lung Epithelial Cells in Vitro," Journal of Clinical Investigation (January, 1993) 91:38-45; Ramsey et al., "Efficacy of Aerosolized Tobramycin in Patients with Cystic Fibrosis," The New England Journal of Medicine (June, 1993) 328:1740-1746; Vasconcellos et al., "Reduction in Viscosity of Cystic Fibrosis Sputum in Vitro by Gelsolin," Science (February, 1994) 263:969-971; Hubbard, McElvaney, and Birrer, "A Preliminary Study of Aerosolized Recombinant Human Deoxyribonuclease I in the Treatment of Cystic Fibrosis," New England J. Med. (1992) 326:812-815; Ranasinha, Assoufi, and Shak, "Efficacy and Safety of Short-Term Administration of Aerosolized Recombinant Human DNase I in Adults with Stable Stage Cystic Fibrosis," Lancet (1993) 342:199-202; Ramsey, Astley, and Aitken, "Efficacy and Safety of Short-Term Administration of Aerosolized Recombinant Human Deoxyribonuclease in Patients with Cystic Fibrosis," Am. Rev. Respir. Dis. (1993) 148:145-151; and Fuchs et al. "Effect of Aerosolized Recombinant Human DNase on Exacerbations Of Respiratory Symptoms and on Pulmonary Function in Patients with Cystic Fibrosis," The New

- 7 -

England Journal of Medicine (September, 1994)  
331:10:637-642.)

Discussion of alkylaryl polyether  
alcohol polymers, including tyloxapol.

5                   It is additionally noted that alkylaryl  
polyether alcohol polymers are a known class of  
polymers and are used commercially as surface active  
detergents and wetting agents (U.S. Patent 2,454,541,  
issued in 1948 to Bock and Rainey, assignors to Rohm &  
10 Haas). The best known of this class is tyloxapol, a  
polymer of 4-(1,1,3,3-tetramethylbutyl)phenol with  
formaldehyde and oxirane.

                  Moreover, tyloxapol is relatively nontoxic  
and does not hemolyze red blood cells in a thousand  
15 times the concentrations at which other detergents are  
hemolytic (Glassman, H.N. Science (1950) 111:688-689).  
Tyloxapol has been used in human pharmacologic  
formulations for over 30 years (Tainter, M.L., et al.  
New England Journal of Medicine (1955) 253:764-767).

20                   For instance, a composition sold by Winthrop  
Laboratories (a division of Sterling Drug, Inc.) and by  
Breon Laboratories (a subsidiary of Sterling Drug,  
Inc.) under the trademark ALEVAIRE®, containing 0.125%  
SUPERINONE® (brand of tyloxapol) in combination with 2%  
25 sodium bicarbonate and 5% glycerin, had been marketed  
for about 30 years for treatment of mucous secretions  
in patients with diseases and disorders such as chronic  
bronchitis, croup, pertussis, and poliomyelitis. (See,  
for example, a product brochure entitled "ALEVAIRE®  
30 Detergent Aerosol for Inhalation" (November, 1965)  
distributed by Breon Laboratories.)

                  However, in December of 1981, ALEVAIRE® was  
withdrawn by the Food and Drug Administration for lack  
of efficacy for treatment of mucous secretions in  
35 patients with diseases and disorders such as chronic  
bronchitis, croup, pertussis, and poliomyelitis because

- 8 -

it was found that there was no evidence that the tyloxapol in ALEVAIRE® had any effect on secretions in the lung from diseases such as chronic bronchitis other than that of water in thinning secretions by simple dilution, and that papers in the manufacturer's bibliography were based on clinical impression and did not reflect adequate controls. (See, letter dated May 27, 1994 to Dr. Thomas Kennedy, one of the co-inventors of the present application, from Ms. Carolann W. Hooton, Chief, Freedom of Information Office, Center for Drug Evaluation and Research, Department of Health & Human Services, Public Health Service, Food and Drug Administration, Rockville, Maryland.)

Surprisingly, the present inventors have found that a mucolytic agent, namely tyloxapol, used years ago in treatment of adult chronic bronchitis (see, discussion below vis-a-vis withdrawal of ALEVAIRE® from the market place by the Food and Drug Administration) dramatically reduces the viscoelastic properties of cystic fibrosis sputum (see, Example IV below).

#### Synopsis of background discussion.

Antioxidants are compounds that can be easily oxidized to stable chemical forms. They can protect chemical and biologic systems by sacrificing themselves to oxidation in preference to oxidation of critically important chemical and biologic molecules. Not all oxidizable compounds can perform an antioxidant function. To successfully protect chemical and biologic systems from oxidants, the antioxidant must have a higher reactivity for the oxidant than the chemical or biologic molecule which it seeks to protect. It is theoretically possible to synthesize a multitude of compounds with antioxidant properties. However, the factor limiting use of these antioxidants

-9-

as treatments in biologic systems is the inherent toxicity of the antioxidant compounds themselves.

Thus, it is a major advantage to discover that a class of commonly used and nontoxic ingredients in medicinal pharmacologic preparations are also potent antioxidants. Not only can such compounds react with partially reduced  $O_2$  species, but they can be used as treatments for oxidant mediated diseases without themselves causing toxicity to biologic systems. Additionally, it is a major advantage to discover that for a patient with cystic fibrosis, they can be used as mucociliary clearance agents for cystic fibrosis sputum, as inhibitors of monocyte tumor necrosis factor secretion, and as inhibitors of production of interleukin-8.

#### SUMMARY OF THE INVENTION

As explained below, this invention in the present Continuation-in-Part describes how alkylaryl polyether alcohol polymers, such as tyloxapol, are useful as treatment agents for mucociliary clearance, as inhibitors of monocyte tumor necrosis factor secretion, and as inhibitors of production of interleukin-8 in cystic fibrosis patients. Administration may be the same as described in U.S. Patent No. 5,474,760 and U.S. Serial No. 08/039,732 (which describe how alkylaryl polyether alcohol polymers are useful as antioxidants in blocking oxidant reactions and biologic injury from partially reduced  $O_2$  species) and is repeated below for clarity.

It is the object of the present invention to provide a method to inhibit oxidant chemical reactions caused by partially reduced  $O_2$  species.

It is a further object of the present invention to provide a method to protect mammalian tissues against injury from partially reduced  $O_2$  species.

-10-

It is a further object of the present invention to provide a method and a medicament for the treatment of cystic fibrosis in patients having the disease to protect the patients from airway injury by  
5 HOCl/OCl, which for convenience, is referred to herein also as HOCl.

It is a further object of the present invention to provide a method for inhibiting oxidant chemical reactions caused by partially reduced O<sub>2</sub>  
10 species by aerosol treatment with the therapeutic agent.

It is a further object of the present invention to provide a method for inhibiting oxidant chemical reactions caused by partially reduced O<sub>2</sub>  
15 species by topical application of the therapeutic agent to the skin.

It is a further object of the present invention to provide a method and a medicament for the mucociliary clearance of cystic fibrosis sputum in  
20 patients having cystic fibrosis to protect the patients from airway injury, for instance, by aerosol treatment with the medicament.

It is a further object of the present invention to provide a method and a medicament for the  
25 inhibition of monocyte tumor necrosis factor secretion, (thus, ameliorating the cachexia and/or anorexia suffered by patients with cystic fibrosis lung disease) and for the reduction of airway injury by inhibiting local production of the chemoattractant interleukin-8.

30 It is an advantage of the present invention that the therapeutic agent is produced from a toxicologically characterized class of compounds with low toxicologic potential to biologic systems.

Consideration of the specification, including  
35 the several figures and examples to follow, will enable one skilled in the art to determine additional objects and advantages of the invention.

-11-

The present invention provides a medicament for the inhibition of injurious effects of partially reduced O<sub>2</sub> species in chemical and biologic systems comprising a treatment effective amount of tyloxapal  
5 alkylaryl polyether alcohol polymers.

Also, the present invention provides a method and medicament comprising administering to a mammal having cystic fibrosis a treatment effective amount of tyloxapol and related alkylaryl polyether alcohol  
10 polymers.

In preferred embodiments of the invention, the medicament is directly instilled into the respiratory system and administered by aerosolization. In this embodiment, the medicament preferably includes  
15 a physiologically acceptable carrier which may be selected from the group consisting of physiologically buffered saline, isotonic saline, and normal saline and an additional treatment effective amount of cetyl alcohol. The pH of the alkylaryl polyether alcohol  
20 polymer and carrier mixture is preferably greater than 6.5 but equal to or less than 7.4.

In other preferred embodiments of the invention, the medicament is applied topically to the skin. In this embodiment, the medicament preferably  
25 includes a physiologic carrier selected from a commercially available petrolatum based ointment or U.S.P. cold cream.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Reference to the following detailed  
30 description may help to better explain the invention in conjunction with the drawings in which:

Figure 1 shows the proposed structure of the class of compounds known as alkylaryl polyether alcohol polymers, wherein R = ethylene, R<sub>1</sub> = tertiary octyl,  
35 x is greater than 1, and y = 8 to 18;

-12-

Figure 2 shows a graph of the inhibitory effect of tyloxapol on  $\cdot\text{OH}$  generation by the Fenton reaction, as measured by hydroxylation of salicylate;

Figure 3 shows a graph of the inhibitory effect of tyloxapol on  $\cdot\text{OH}$  generation by the Fenton reaction, as measured by oxidation of the sugar, 2-deoxyribose;

Figure 4 shows lung wet/dry weight ratios in rats exposed to 100% oxygen and treated with normal saline, tyloxapol, and tyloxapol plus cetyl alcohol; and

Figure 5 shows pleural fluid accumulation in rats exposed to 100% oxygen and treated with normal saline, tyloxapol, and tyloxapol plus cetyl alcohol.

#### 15                    DETAILED DESCRIPTION OF THE INVENTION

Alkylaryl polyether alcohol polymers can in general be synthesized by condensing alkylaryl alcohols with formaldehyde, as described by Bock and Rainey in U.S. Patent 2,454,541 (1948, assigned to Rohm & Haas), the disclosure of which is incorporated herein by reference. All alkylaryl polyether alcohol polymers disclosed in this patent should work in the present invention. Several specific alkylaryl polyether alcohol polymers can be easily synthesized by methods previously described (J.W. Conforth, et al. Nature (1951) 168:150-153). The prototype compound of this class, tyloxapol, can be conveniently purchased in pharmacologically acceptable purity from Rohm and Haas Co., Philadelphia, PA.

30                    Treatment of cystic fibrosis patients for mucociliary clearance of cystic fibrosis sputum, inhibition of monocyte tumor necrosis factor secretion, and inhibition of production of interleukin-8 with alkylaryl polyether alcohol polymers, particularly  
35 tyloxapol, is essentially the same as the

-13-

administration described in U.S. Patent No. 5,474,760 and U.S. Serial No. 08/039,732.

More specifically, for treatment of mammalian respiratory conditions related to overproduction of partially reduced O<sub>2</sub> species, and for mucociliary clearance of cystic fibrosis sputum, inhibition of monocyte tumor necrosis factor secretion, and inhibition of production of interleukin-8, the alkylaryl polyether alcohol polymer is dissolved in sterile 0.9% NaCl for injection, and the pH is adjusted to approximately 7.0 by addition of NaOH or HCl. A nonpolymeric alkyl or aryl alcohol such as cetyl alcohol (hexadecanol) may be added equivalent to 1 to 1.5 times the weight of tyloxapol to increase the effectiveness of the mixture in protection against oxidant injury.

This mixture is then administered to the lung by direct instillation into the respiratory system. The mixture may also be administered by aerosolization using a clinically available positive pressure driven nebulizer that produces respirable particles of less than 5 microns mass median diameter.

As an example, a 0.125% solution of tyloxapol is made in sterile 0.9% NaCl and double glass distilled deionized water to make it isotonic with respect to respiratory secretions. The pH is adjusted to approximately 7.0 to prevent bronchospasm from extremes of acidity or alkalinity. This mixture is sterilized by vacuum filtration through a 0.22 micron Millipore filter and 3.3 ml each is packaged into 5 ml unit dose glass vials with rubber stoppers fastened with aluminum crimp-on "flip tear" seals. To provide additional sterilization of product, unit dose vials are terminally autoclaved 12-14 minutes at 125 degrees Centigrade. A 5% concentration of glycerol may be optionally added to the above mixture to stabilize droplet size during aerosolization.



-14-

For administration of treatment effective doses, 3 ml of sterile tyloxapol solution is inhaled as an aerosol every 4 to 6 hours using a clinically available positive pressure driven nebulizer (Acorn or 5 deVilbiss). Alternatively, the mixture can be nebulized into the respiratory delivery circuit of a mechanical ventilator. A beta sympathetic agonist bronchodilator (such as 1.25 to 2.5 mg of albuterol) can be mixed with the tyloxapol solution and nebulized 10 concomitantly to prevent any transient bronchospasm that might occur from the tyloxapol solution itself.

For treatment of cutaneous oxidant-mediated disorders such as solar burn, a 0.5 to 5% mixture (w/w) is made with an alkylaryl polyether alcohol such as 15 tyloxapol in a commercially available petrolatum based ointment such as Aquaphor (Beiersdorf, Inc., Norwalk, CT), white petrolatum or U.S.P. cold cream as the base vehicle. This mixture is rubbed lightly onto the affected skin area 3 to 4 times daily.

20 In order to facilitate a further understanding of the invention, the following examples primarily illustrate certain more specific details thereof.

Example I demonstrates the potent activity of 25 alkylaryl polyether alcohol polymers as OH inhibitors in chemical systems. Example II demonstrates the therapeutic benefit of using alkylaryl polyether alcohol polymers to prevent mammalian lung injury from exposure to 100% oxygen. Example III demonstrates the 30 potent activity of alkylaryl polyether alcohol polymers as scavengers of HOCl in chemical systems. Example IV demonstrates the activity of tyloxapol as a mucolytic agent for sputum from cystic fibrosis patients. Example V demonstrates suppression of cytokine 35 production and of interleukin-8 production.

-15-

EXAMPLE 1Inhibitions of OxidantsGenerated by the Fenton Reaction.

5 The first chemical system used to test the antioxidant activity of alkylaryl polyether alcohol polymers employed salicylate as the target molecule of oxidants. Hydroxyl radical reacts with salicylic acid (2 hydroxybenzoic acid) to produce two dihydroxybenzoic acid products, 2,3- and 2,5-dihydroxybenzoic acid.

10 These hydroxylated products provide evidence of  $\cdot\text{OH}$  generation (R.A. Floyd et al. Journal of Biochemical and Biophysical Methods (1984) 10:221-235; R.A. Floyd et al. Journal of Free Radicals in Biology & Medicine (1986) 2:13-18).

15 The detection of 2,3- and 2,5-dihydroxybenzoic acid was performed using high performance liquid chromatography with electrochemical detection. Suspensions of 10  $\mu\text{M}$   $\text{FeCl}_3$ , 1.0  $\text{mM}$   $\text{H}_2\text{O}_2$ , 1.0  $\text{mM}$  ascorbate, and 10.0  $\mu\text{M}$  salicylic acid were employed

20 to generate and detect  $\cdot\text{OH}$ . Either 0.1 ml of normal saline or tyloxapol (final concentrations of 0.0 to 10  $\text{mg/ml}$ ) were added. The reaction mixtures were incubated at 45 degrees Centigrade for 30 min and centrifuged at 1200 g for 10 min. Supernatant was

25 centrifuged (Beckman Microfuge E) through a 0.22  $\mu\text{m}$  microfuge tube filter (PGC Scientific No. 352-118) at 15,000 g.

A 100  $\mu\text{L}$  sample of the eluate was injected onto a C18 RP HPLC column (250 x 4.7 mm, Beckman No. 235329).

30 Hydroxylated products of salicylate were quantified with a Coulochem electrochemical detector (ESA model 5100A) with the detector set at a reducing potential of -0.40 VDC. The guard cell (used as a screen) was set at an oxidizing potential of +0.40 VDC.

35 Measurements were done in duplicate. Figure 2 shows that the addition of tyloxapol to the reaction mixture

-16-

inhibited OH generation in a concentration dependent manner.

The second chemical system used to test the antioxidant activity of alkylaryl polyether alcohol polymers employed 2-deoxyribose as the target molecule of oxidants. This pentose sugar reacts with oxidants to yield a mixture of products. On heating with thiobarbituric acid (TBA) at low pH, these products form a pink chromophore that can be measured by its absorbance at 532 nm (B. Halliwell and J.M.C. Gutteridge. Methods in Enzymology (1990) 186:1-85).

The chemical system employed to generate oxidants was a reaction mixture containing 10.0 uM FeCl<sub>3</sub>, 1.0 mM ascorbate, 1.0 mM H<sub>2</sub>O<sub>2</sub> and 1.0 mM deoxyribose in Hanks Balanced Salt Solution. This system is useful for measuring site-specific OH generation on biologic molecules, as described by Halliwell and Gutteridge in the reference immediately above. Either 0.1 ml of normal saline or tyloxapol (final concentrations of 0.0 to 10.0 mg/ml) were added.

The reaction mixtures were incubated at 45 degrees Centigrade for 30 min and centrifuged at 1200 g for 10 min. One ml of both 1.0% (w/v) TBA and 2.8% (w/v) trichloroacetic acid were added to 1.0 ml of supernatant, heated at 100 degrees Centigrade for 10 min, cooled in ice, and the chromophore determined in triplicate by its absorbance at 532 nm. Figure 3 shows that the addition of 10 mg/ml tyloxapol to the reaction mixture causes marked inhibition of the oxidation of deoxyribose, as measured by absorbance of the oxidant reaction produced at 532 nm.

The third system used to test the antioxidant activity of alkylaryl polyether alcohol polymers employed asbestos as the source of iron for oxidant generation and 2-deoxyribose as the target molecule of oxidants. The generation of oxidants by asbestos has been described previously (A.J. Ghio et al. American

-17-

Journal of Physiology (Lung Cellular and Molecular Physiology 7) (1992) 263:L511-L518). The reaction mixture, in a total volume of 2.0 ml phosphate-buffered saline (PBS), contained the following reagents: 1.0 mM deoxyribose, 1.0 mM H<sub>2</sub>O<sub>2</sub>, 1.0 mM ascorbate, and 1.0 mg/ml crocidolite asbestos. The mixture was incubated at 37 degrees Centigrade for 1 h with agitation and then centrifuged at 1,200 g for 10 min.

Oxidant generation was assessed by measuring TBA reactive products of deoxyribose as detailed in the paragraph above. Measurements were done in triplicate. TABLE I below shows that the addition of tyloxapol inhibited in a concentration dependent manner the generation of oxidants by asbestos, as measured by absorbance of the oxidant reaction product at 532.

TABLE I

Effect of Tyloxapol on Oxidant Generation of Asbestos

	Absorbance at 532 nm
Tyloxapol 0.0 mg/ml	0.93 ± 0.02
Tyloxapol 0.1 mg/ml	0.89 ± 0.04
20 Tyloxapol 1.0 mg/ml	0.75 ± 0.01
Tyloxapol 10.0 mg/ml	0.53 ± 0.04

EXAMPLE IIProtection from Mammalian Lung Injury by 100% Oxygen

To determine if alkylaryl polyether alcohol polymers could protect against oxidant injury to intact biologic systems, this treatment was studied in a well established model of oxygen toxicity to the lung (J.F. Turrens, et al. Journal of Clinical Investigation (1984) 73:87-95). Sixty-day old male Sprague-Dawley rats (Charles River, Inc., Wilmington, MA) were tracheally instilled with 0.5 ml of either normal saline, tyloxapol (6.0 mg) or tyloxapol (6.0 mg) and

-18-

cetyl alcohol (hexadecanol, 11.0 mg). These rats (n=10 in each treatment group) were then exposed to either air or 100% oxygen in plexiglass chambers at a flow rate of 10 liters/min.

5           Oxygen percentage was monitored by a polarographic electrode and maintained continuously above 98%. Temperature was maintained between 20 and 22 degrees Centigrade. Survival times were determined by checking animals every 4 hours. Separate groups of  
10 rats treated similarly (n=10 in each treatment group) were exposed to 100% oxygen for 61 hours, and then were euthanized with 100mg/kg intraperitoneal pentobarbital. Pleural fluid volume was measured by aspirating pleural  
15 the diaphragm. Lung wet/dry weight ratios were calculated from the left lung after drying the tissue for 96 hours at 60 degrees Centigrade. Survival data is shown TABLE II below.

20           Rats receiving intratracheal tyloxapol had markedly improved survival compared to placebo control animals instilled with saline. The protective effect of tyloxapol was further enhanced by combining it with cetyl alcohol.

-19-

TABLE II

Effect of Tyloxapol On Oxygen Toxicity In Rats

<u>Hours</u>		<u>Percent Survival</u>		
		Saline	Tyloxapol	Tyloxapol/ Cetyl Alcohol
	0	100	100	100
5	58	100	100	100
	62	83	100	100
	66	42	100	100
	70	17	75	100
	72	17	75	100
10	76	8	58	100
	80	8	58	100
	84	8	58	100
	88	8	58	100
	92	0	58	100
15	96	0	58	100

Lungs wet/dry weight ratios were substantially lower in rats treated with tyloxapol or tyloxapol and cetyl alcohol (Figure 4), demonstrating that tyloxapol or the combination of tyloxapol and cetyl alcohol protect against edema formation from oxidant injury. Rats treated with tyloxapol or the combination of tyloxapol and cetyl alcohol also had less pleural fluid accumulation than saline treated controls (Figure 5).

These results demonstrate the ability of alkylaryl polyether alcohol polymers such as tyloxapol to protect against oxidant tissue injury. The survival studies (TABLE II) further demonstrate that the protective effect of the medicament is enhanced by combining it with alcohols such as cetyl alcohol.

-20-

EXAMPLE IIIScavenging of HOCl.

The activity of tyloxapol to scavenge  $\text{OCl}^-$  was tested studying its ability to prevent  $\text{OCl}^-$  medicated oxidant conversion of diethanolamine to its corresponding chloramine ("Determination of HOCl Production by Micloperoxidase", Robert A. Greenwald, editor, Handbook of Methods for Oxygen Radical Research, CRC Press, Boca Raton, Florida (1987), page 300).

The reaction mixture comprised 0.9 ml of 10.0 mM diethanolamine in 0.1 M sodium acetate buffer, pH of 4.5. To this resultant was added either 100 microliters of 0.1 M NaCl or tyloxapol in 0.1 M NaCl, and the baseline absorbance was read at 280 nm. NaOCl was added to a final concentration of 10 mM.

The reaction mixture was incubated 15 minutes, and the absorbance was measured at 280 nm. The difference in  $A_{280}$  before and after addition of NaOCl was used as a measure of concentration of the stable chloramine. Experiments were performed in triplicate. Results are summarized in Table III below.

TABLE III

	<u>Microliters of Tyloxapol (10 mg/ml)</u>	<u>Absorbance (Mean + SD)</u>
25	0	0.505 ± 0.002
	25	0.468 ± 0.008
	50	0.444 ± 0.023
	75	0.377 ± 0.010
30	100	0.319 ± 0.025

Thus, tyloxapol is a potent inhibitor of the oxidant activity of HOCl, and should be useful in preventing HOCl medicated oxidant injury of the airway in diseases such as cystic fibrosis. Administration of tyloxapol by tracheal installation to cystic fibrosis patients should inhibit HOCl produced in these patients

-21-

and therefore protect them from oxidant injury. The result should be even better if some cetyl alcohol is admixed with the tyloxapol; preferably, the cetyl alcohol is added in 1 to 1.5 times the weight of the tyloxapol.

Preparation of samples for administration to the patient should be the same as described above in the "DETAILED DESCRIPTION OF THE INVENTION" section herein, most preferably inhalation of 3 ml of a 0.125% solution of tyloxapol by jet aerosol every 4 to 6 hours.

#### EXAMPLE IV

##### Treatment of Sputum from Cystic Fibrosis Patients with Tyloxapol.

For testing with tyloxapol, sputum was obtained from 11 test subjects who were cystic fibrosis patients and not being treated with any medicament (designated below as CF group). Also, for testing with tyloxapol, sputum was obtained from 3 test subjects who were cystic fibrosis patients being treated with DNase (designated below as CF/with DNase group).

Additionally, for comparison testing with tyloxapol sputum was obtained from 2 test subjects who were adult bronchiectases patients (designated below as AB group), and 3 test subjects who were healthy, normal, free of disease, persons (designated below as Control group). Moreover, as part of the comparison testing, sputum samples (CF, CF/with DNase, AB, and Control) were tested with saline.

Sputum samples were tested as follows. Sputum viscosity was studied using a Brookfield cone/plate viscometer (Brookfield Engineering Laboratories, Inc., Stoughton, MA). Sputum (750 microliters) was mixed 3:1 with 0.9% saline or with 0.125% tyloxapol in saline (250 microliters), vortexed 30 seconds, and then incubated 15 minutes at 37 degrees



-22-

Centigrade. Because the initial viscosity of CP sputum of patients 1 and 9 was too high for measurement, their CF sputum was diluted 1:3 and 1:1, respectively, with saline or tyloxapol in saline.

5           The results clearly illustrated that for sputum from the CF group, tyloxapol had a dramatic effect in decreasing the viscosity as compared to simple dilution of sputum with saline, (i.e., sputum mean average viscosity went down 32.3 cp, that is from  
10 44.7 cp for saline down to 12.4 cp for tyloxapol with saline for the CF group), but for sputum from the AB group, tyloxapol was largely ineffective in decreasing the viscosity as compared to simple dilution of sputum with saline, (i.e., sputum mean average viscosity went  
15 down only 2.7 cp, that is from 6.9 cp for saline down to 4.2 cp for tyloxapol with saline). The results are summarized in Table IV below.

-23-

TABLE IVEffect of Tyloxapol on Viscosity of Sputum

<u>Test Subject</u>		<u>Sputum Viscosity in Centipoise (mPa-s) at 0.3 RPM</u>	
<u>Group</u>	<u>No.</u>	<u>Saline</u>	<u>Tyloxapol in Saline</u>
5	CF		
	1	19.1	1.5
	2	49.0	6.1
	3	51.3	30.6
	4	88.7	31.4
	5	153.3	49.8
	6	35.2	1.5
	7	26.1	6.9
	8	10.8	2.3
	9	7.7	1.5
	10	15.4	3.1
	11	34.6	1.5
	Mean Average	44.7±12.9	12.4±5.1
	CF with DNase		
	1	10.0	9.2
	2	6.9	4.6
	3	4.6	1.5
	Mean Average	7.2±1.6	5.1±2.2
	AB		
	1	6.9	3.8
	2	6.9	4.6
10	Mean Average	6.9	4.2
	Control		
	1	3.1	1.5
	2	0	0
	3	8.4	0
	Mean Average	3.8±2.5	0.5±0.5

-24-

Thus, tyloxapol is a potent agent for decreasing viscosity of cystic fibrosis sputum, and should be useful in preventing injury of the airway in diseases such as cystic fibrosis. Administration of tyloxapol by tracheal installation to cystic fibrosis patients should work for mucociliary clearance of sputum produced in these patients and therefore protect them from injury. The result should be even better if some cetyl alcohol is admixed with the tyloxapol; preferably, the cetyl alcohol is added in 1 to 1.5 times the weight of the tyloxapol. Preparation of samples for administration to the patient should be the same as described above in the "DETAILED DESCRIPTION OF THE INVENTION" section herein, most preferably inhalation of 3 ml of a 0.125% solution of tyloxapol by jet aerosol every 4 to 6 hours.

#### EXAMPLE V

##### Suppression of Cytokine Production by Tyloxapol as Related to Cystic Fibrosis Patients.

Cachexia and/or anorexia prominent in patients with severe cystic fibrosis lung disease is caused by an increased rate of tumor necrosis factor (TNF) gene transcription and secretion by cystic fibrosis macrophages. (See, Pfeffer, Huecksteadt, and Hoidal, "Expression and Regulation of Tumor Necrosis Factor in Macrophages from Cystic Fibrosis Patients," Am. J. Respir. Cell. Mol. Biol. (1993) 9:511-519.) Tyloxapol should also ameliorate this aspect of adverse cystic fibrosis pathophysiology when administered to cystic fibrosis patients because, as shown below, it is a potent suppressant of TNF secretion by monocyte-macrophage cell lines.

Monocytes were prepared by mixing venous blood of healthy human volunteers with an equal volume of sterile isotonic saline/10mM HEPES. The mixture was placed into 50 ml conical polypropylene tubes in 30 ml

-25-

aliquots. Each aliquot of diluted blood was underlaid with 20 to 25 ml of sterile Lymphocyte Separation Medium (LSM; Organon-Technika, Durham, North Carolina).

The tubes were centrifuged at 400 g for 40 minutes at room temperature. The mononuclear cells at the interface were removed and washed twice in sterile isotonic saline/10mM HEPES, followed by a wash in RPMI-1640. Purified monocytes were suspended at  $2 \times 10^6$  cells/ml in RPMI supplemented with 100 U/ml penicillin, 100 ug/ml streptomycin, 2 mM L-glutamine, 1mM pyruvate, 1% non-essential amino acids, 25 mM HEPES, and 5% heat-inactivated human serum.

To each well of a 48-well flat bottomed tissue culture plate was added 0.5 ml of cell suspension. Tyloxapol (diluted in complete medium at 4X the desired final concentration) was added in 250 ul volumes to each well. Control wells received 250 ul of complete medium.

Cell suspensions were incubated 16 hours at 37°C. in humidified 5% carbon dioxide in the presence or absence of 100 ng/ml Salmonella typhosa lipopolysaccharide as a stimulant of cytokine production.

After incubation, supernatants were aspirated off, and the unattached cells and cell debris were removed by filtration. The release of cytokines was determined in the cell free supernatants using ELISA capture assays. The concentration of tyloxapol effective at inhibiting secretion of each tested cytokine by 50% ( $EC_{50}$ ) is summarized in Table V below (interleukin is abbreviated as IL).

-26-

TABLE V

Tyloxapol Inhibition of Monocyte Cytokine Production

	<u>Cytokine</u>	<u>EC<sub>50</sub> (mcg/ml)</u>
	TNF-alpha	30
5	IL1-beta	60
	IL-6	30
	IL-8	70

Thus, tyloxapol, as a potent inhibitor of monocyte TNF secretion, should ameliorate the cachexia and/or anorexia suffered by patients with cystic fibrosis lung disease. Also, because interleukin-8 (IL-8) is an important chemotactic mediator perpetuating inflammation in the airway of cystic fibrosis patients (see, Nakamura, Yoshimura, McElvaney, and Crystal, "Neutrophil Elastase in Respiratory epithelial Lining Fluid of Individuals with Cystic Fibrosis Induces Interleukin-8 Gene Expression in a Human Bronchial Epithelial Cell Line," J. Clin. Invest. (1992) 89:1478-1484; and McElvaney, Nakamura, and Birrer, "Modulation of Airway Inflammation in Cystic Fibrosis. In Vivo Suppression of Surface by Aerosolization of Recombinant Secretory Leucoprotease Inhibitor," J. Clin. Invest. (1992) 90:1296-1301), tyloxapol should also reduce airway injury by inhibiting local production of the chemoattractant IL-8.

Hence, administration of tyloxapol by tracheal installation to cystic fibrosis patients should work as a potent inhibitor of monocyte TNF secretion, and should ameliorate the cachexia and/or anorexia suffered by patients with cystic fibrosis lung disease and should also reduce airway injury by inhibiting local production of the chemoattractant IL-8, and should therefore protect the cystic fibrosis

-27-

patients from injury. The result should be even better if some cetyl alcohol is admixed with the tyloxapol; preferably, the cetyl alcohol is added in 1 to 1.5 times the weight of the tyloxapol. Preparation of

5 samples for administration to the patient should be the same as described above in the "DETAILED DESCRIPTION OF THE INVENTION" section herein, most preferably inhalation of 3 ml of a 0.125% solution of tyloxapol by jet aerosol every 4 to 6 hours.

10 The appended claims set forth various novel and useful features of the invention.

-28-

## WHAT IS CLAIMED IS:

1. A method for the treatment of cystic fibrosis disease entities resultant from overproduction of HOCl comprising administering to a mammal having cystic fibrosis disease an amount of alkylaryl polyether alcohol with formaldehyde and oxirane polymer effective to inhibit oxidant chemical reactions caused by the oxidant species in the mammal, thereby treating the mammalian disease entities.  
5
2. The method of Claim 1, wherein said administering of alkylaryl polyether alcohol with formaldehyde and oxirane polymer comprises administering of 4-(1,1,3,3-tetramethylbutyl)phenol with formaldehyde and oxirane polymer.  
10
3. The method of Claim 1, wherein said administering comprises administering the polymer directly into the mammals respiratory tract.  
15
4. The method of Claim 1, wherein said administering comprises administering of the polymer by aerosolization.
5. The method of Claim 1, wherein said administering comprises administering of the polymer including a physiologically acceptable carrier.  
20
6. The method of Claim 5, wherein said administering comprises including that said carrier is selected from physiologically buffered solutions.  
25
7. The method of Claim 6, wherein said administering comprises including that the physiologically buffered solutions are selected from

-29-

the group consisting of isotonic saline, normal saline, and combinations thereof.

8. A method for the mucociliary clearance of cystic fibrosis sputum, said method comprising  
5 administering to a mammal having cystic fibrosis disease an amount of an alkylaryl polyether alcohol with formaldehyde and oxirane polymer effective to decrease the viscosity of the sputum in the mammal, thereby providing for the mucociliary clearance of the  
10 cystic fibrosis sputum:

9. The method of Claim 8, wherein said administering of alkylaryl polyether alcohol with formaldehyde and oxirane polymer comprises  
administering of 4-(1,1,3,3-tetramethylbutyl)phenol  
15 with formaldehyde and oxirane polymer.

10. The method of Claim 8, wherein said administering comprises administering the polymer directly into the mammal's respiratory tract.

11. The method of Claim 8, wherein said  
20 administering comprises administering of the polymer by aerosolization.

12. The method of Claim 8, wherein said administering comprises administering of the polymer including a physiologically acceptable carrier.

25 13. The method of Claim 12, wherein said administering comprises including that said carrier is selected from physiologically buffered solutions.

14. The method of Claim 13, wherein said administering comprises including that the  
30 physiologically buffered solutions are selected from



-30-

the group consisting of isotonic saline, normal saline, and combinations thereof.

15           15. The method of Claim 8, wherein said administering comprises administering of the polymer including DNase.

10           16. A method for the inhibition of tumor necrosis factor secretion, said method comprising administering to a mammal having cystic fibrosis disease an amount of an alkylaryl polyether alcohol with formaldehyde and oxirane polymer effective to inhibit monocyte tumor necrosis factor secretion in the mammal, thereby providing for the amelioration of cachexia and/or anorexia suffered by mammals with cystic fibrosis lung disease.

15           17. The method of Claim 16, wherein said administering of alkylaryl polyether alcohol with formaldehyde and oxirane polymer comprises administering of 4-(1,1,3,3-tetramethylbutyl)phenol with formaldehyde and oxirane polymer.

20           18. The method of Claim 16, wherein said administering comprises administering the polymer directly into the mammal's respiratory tract.

            19. The method of Claim 16, wherein said administering comprises administering of the polymer by aerosolization.

            20. The method of Claim 16, wherein said administering comprises administering of the polymer including a physiologically acceptable carrier.

-31-

21. The method of Claim 20, wherein said administering comprises including that said carrier is selected from physiologically buffered solutions.

22. The method of Claim 21, wherein said  
5 administering comprises including that the physiologically buffered solutions are selected from the group consisting of isotonic saline, normal saline, and combinations thereof.

23. A method for the inhibition of  
10 production of interleukin-8, said method comprising administering to a mammal having cystic fibrosis disease an amount of an alkylaryl polyether alcohol with formaldehyde and oxirane polymer effective to inhibit production of interleukin-8 in the mammal,  
15 thereby providing for the amelioration of airway injury in mammals with cystic fibrosis lung disease.

24. The method of Claim 23, wherein said administering of alkylaryl polyether alcohol with formaldehyde and oxirane polymer comprises  
20 administering of 4-(1,1,3,3-tetramethylbutyl)phenol with formaldehyde and oxirane polymer.

25. The method of Claim 23, wherein said administering comprises administering the polymer directly into the mammal's respiratory tract.

25 26. The method of Claim 23, wherein said administering comprises administering of the polymer by aerosolization.

27. The method of Claim 23, wherein said administering comprises administering of the polymer  
30 including a physiologically acceptable carrier.

-32-

28. The method of Claim 27, wherein said administering comprises including that said carrier is selected from physiologically buffered solutions.

29. The method of Claim 28, wherein said  
5 administering comprises including that the physiologically buffered solutions are selected from the group consisting of isotonic saline, normal saline, and combinations thereof.




FIG. 1




FIG. 2

2/3




FIG. 3




FIG. 4

3/3




FIG. 5

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup>:</b> <b>A61K 31/77</b>	<b>A3</b>	<b>(11) International Publication Number:</b> <b>WO 96/30028</b> <b>(43) International Publication Date:</b> 3 October 1996 (03.10.96)
<b>(21) International Application Number:</b> PCT/US96/04309 <b>(22) International Filing Date:</b> 29 March 1996 (29.03.96) <b>(30) Priority Data:</b> 413,699 30 March 1995 (30.03.95) US <b>(60) Parent Application or Grant</b> <b>(63) Related by Continuation</b> US 08/413,699 (CIP) Filed on 30 March 1995 (30.03.95) <b>(71) Applicant (for all designated States except US):</b> DUKE UNIVERSITY [US/US]; 230 North Building, Research Drive, Durham, NC 27708-0083 (US). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> GHIO, Andrew, J. [US/US]; 211 Brandemill Drive, Durham, NC 27713 (US). PIANTADOSI, Claude, A. [US/US]; 3808 Kildrummy Drive, Durham, NC 27705 (US). KENNEDY, Thomas, P. [US/US]; 213 Grande Drive, Richmond, VA 23229 (US). <b>(74) Agents:</b> McCOY, Michael, D. et al.; Bell, Seltzer, Park & Gibson, P.O. Drawer 34009, Charlotte, NC 28234 (US).	<b>(81) Designated States:</b> AL, AM, AT, AT (Utility model), AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), EE, EE (Utility model), ES, FI, FI (Utility model), GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> <b>(88) Date of publication of the international search report:</b> 12 December 1996 (12.12.96)	
<b>(54) Title:</b> METHOD OF MUCOCILIARY CLEARANCE IN CYSTIC FIBROSIS PATIENTS USING ALKYLARYL POLYETHER ALCOHOL POLYMERS <b>(57) Abstract</b> <p>A method and medicament for the inhibition of oxidants comprising administering a treatment effective amount of alkylaryl polyether alcohol polymers to a chemical or biologic system in need thereof. Also, a method and medicament for mucociliary clearance, inhibition of cytokine production, and inhibition of interleukin-8 production in cystic fibrosis patients. The method involves administering a treatment effective amount of alkylaryl polyether alcohol polymers to a chemical or biologic system in need thereof. The medicament is preferably administered by aerosolization into the mammalian respiratory system. The medicament may also be applied to the mammalian skin. Preferably, the medicament includes a physiologically acceptable carrier which may be selected from the group consisting of physiologically buffered saline, isotonic saline, normal saline, petrolatum based ointments and U.S.P. cold cream.</p>		

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam



# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 96/04309

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC 6 A61K31/77		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) IPC 6 A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,94 22425 (DUKE UNIVERSITY) 13 October 1994 see the whole document ---	1-29
X	Z. ERKRANK. ATM. ORG., vol. 139 , no. 2-3, 1974, pages 117-120, XP000603337 J. RUDNIK: "Behandlungsergebnisse von mucoviszidosekranken Kindern in einem Sanatorium" see page 119 --- <div style="text-align: center;">-/--</div>	1-29
<div style="display: flex; justify-content: space-between;"> <span><input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.</span> <span><input checked="" type="checkbox"/> Patent family members are listed in annex.</span> </div>		
<div style="display: flex;"> <div style="flex: 1;"> <p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="flex: 1;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search  <div style="text-align: center;">3 October 1996</div>		Date of mailing of the international search report  <div style="text-align: center;">04. 11. 96</div>
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+ 31-70) 340-3016		Authorized officer  <div style="text-align: center;">Orviz Diaz, P</div>

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 96/04309

C/(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DEUTSCHE MED. WOCHENSCHR., vol. 95, no. 42, 1970, pages 2133-2135, XP000603238 E. ROSSI: "Die moderne Behandlung der Mucoviscidose (zystische Pankreasfibrose)" see page 2134, left-hand column, paragraph 2</p> <p>---</p>	1-29
X	<p>NEW ENG. J. MED., vol. 253, no. 18, 1955, pages 764-767, XP000602461 M.L. TAINTER: "Alevaire as mucolytic agent" cited in the application see the whole document</p> <p>---</p>	8-15
X	<p>J. APPL. PHYSIOL., vol. 77, no. 3, 1994, pages 1217-1223, XP000602565 A. J. GHIO: "Synthetic surfactant scavenges oxidants and protects against hyperoxic lung injury" see the whole document</p> <p>---</p>	1-7
P,X	<p>CLIN. IMMUNOL. IMMUNOPATHOL., vol. 77, no. 2, November 1995, pages 201-205, XP002015023 M.J. THOMASSEN: "Regulation of human alveolar macrophage inflammatory cytokines by tyloxapol: a component of the synthetic surfactant exosurf" see the whole document</p> <p>-----</p>	16-28

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 96/ 04309

**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claim(s) 1 - 29  
is(are) directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**☐ The additional search fees were accompanied by the applicant's protest.☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 96/04309

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9422425	13-10-94	AU-A- 6527394	24-10-94
		CA-A- 2102142	01-10-94
		CA-A- 2159485	13-10-94
		EP-A- 0693921	31-01-96
		US-A- 5474760	12-12-95
		US-A- 5512270	30-04-96
-----			